Brian Brockway and Dr. Robert Hamlin discuss the history of wireless monitoring technology as applied in preclinical physiology, drug-discovery, and safety pharmacology and toxicology applications.
Biotelemetry is without a doubt the preferred approach for obtaining physiological measurements from animal research models in the fields of physiology, pathophysiology, pharmacology, drug discovery, and drug safety assessment. Naturally, the increase in application and availability of wireless measurement devices has fostered new research previously impossible, and motivated the works of many confirming the benefits of implantable telemetry over tethered and restrained animal models. This new era in implantable telemetry, where competition is more the rule than the exception, will drive down costs and expand the range of applications in life science research.
During this webinar sponsored by VivaQuant and QTest Labs, Brian Brockway reviewed the evolution of wireless technology and provided insight in to new possibilities based on recent innovations in the market place. Following, Dr. Robert Hamlin provided an in-depth review of wireless monitoring practices in physiology, drug-discovery, safety pharmacology and toxicology and discussed current industry standards for testing new therapeutic entities through wireless collection of blood pressure, ventricular pressures, blood flow and ECG measurements.
Presenters
Brian Brockway
Founded Data Sciences Intl. (DSI), the leading provider of wireless implantable sensors and systems for preclinical testing of new drugs and biomedical research. Bootstrapped DSI with SBIR grants into a highly profitable business with > $40 mm revenue. Developed domestic and international direct sales and distribution network serving 40 countries on five continents. Named to the Inc. 500 list of America’s fastest growing private companies for three consecutive years. Named SBA Exporter of the Year 1994 and Tibbetts Award winner 1997. DSI received several awards and recognition for technology innovation and creative financing strategies during Brian’s tenure.
Started Transoma Medical in 2003 to leverage the wireless implantable sensor technology and IP portfolio of DSI to develop a line of miniature implantable devices for diagnosis and monitoring of patients with chronic cardiovascular disease. Gained FDA clearance on two implantable devices and achieved $5 mm revenue run rate prior to shuttering the business during the 2009 financial crisis.
Brian has about 80 patents issued and pending in medical devices, sensors, and diagnostics and is co-author of more than 25 scientific publications.
Robert Hamlin
Sponsor
VivaQuant LLC
